

Uppsala, 10 June 2008

Doxa files application for FDA-registration of Xeraspine[®]

Doxa has submitted a 510(k) application for registration of Xeraspine[®] with the American regulatory authority, FDA. We expect a response from the FDA, with possible points for consideration, within three months. FDA approval allows the marketing and sale of Xeraspine in the US.

"This is an important first step in a launch of Xeraspine to the world market and we are proud of this accomplishment" comments Christer Wallin, CEO and President of Doxa.

Xeraspine is the first injectable, high-mechanical-strength bioceramic designed for the treatment of vertebral fractures. Xeraspine provides surgeons with a sophisticated, bone-like bioceramic that is safe, offers effective pain relief and displays excellent handling properties.

Xeraspine has been developed in collaboration with clinicians to provide the special properties they have requested.

Xeraspine[®]

- is bone-like, biocompatible and integrates with surrounding bone tissue,
- has high mechanical strength,
- is stable over time and non-resorbable,
- has a lower hardening temperature than PMMA,
- has excellent radiopacity,
- does not cause coagulation or hemolysis of blood as does e.g. calcium phosphate,
- reduces the risk of leakage through high viscosity, hydrophilicity and cohesiveness,
- does not release dangerous monomers at mixing,
- does not shrink,
- has short mixing time, long working time and short setting time,
- can be meticulously controlled during injection (viscosity).

It is Doxa's opinion that Xeraspine offers decisive advantages when treating vertebral fractures and other spinal indications as compared with PMMA and calcium phosphates.

More than 100 patients have been treated with Xeraspine using percutaneous vertebroplasty as well as kyphoplasty. Two clinical studies have been conducted and a third study is under way. These studies have shown Xeraspine to be very safe, to provide effective pain relief and to offer excellent handling characteristics.

Xeraspine received CE-approval in 2006.

Doxa AB

Christer Wallin, CEO

For further information please call: Christer Wallin. Tel: +46 (0)18-478 2075, mob: +46 (0)70-667 3104, Or Fredrik Alpstén. Tel: +46 (0)18-478 2060, mobil +46 (0)70-667 3106

About Doxa

Doxa is a medtech company located in Uppsala, Sweden. Doxa develops and commercialises new, proprietary biomaterials for use in a range of fields, with current focus on two areas: spinal (vertebral compression fractures) and dental. Doxa has approximately 20 staff most of whom are active in development and manufacture. Investor Growth Capital, SLS Venture, Omega Funds and the founder, Leif Hermansson, are the principal owners, in company with approximately 1,300 other shareholders. Website: www.doxa.se.